Kane Biotech Inc. (CVE:KNE – Get Free Report) Director Philip Renaud sold 2,000,000 shares of the business’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of C$0.13, for a total transaction of C$260,000.00.
Kane Biotech Price Performance
Shares of CVE:KNE opened at C$0.14 on Tuesday. The company has a quick ratio of 0.39, a current ratio of 0.37 and a debt-to-equity ratio of 1,164.24. The company has a 50-day moving average price of C$0.11 and a 200 day moving average price of C$0.09. Kane Biotech Inc. has a 52 week low of C$0.05 and a 52 week high of C$0.17. The company has a market cap of C$18.46 million, a P/E ratio of -4.67 and a beta of 0.56.
Kane Biotech (CVE:KNE – Get Free Report) last posted its quarterly earnings results on Tuesday, March 26th. The company reported C($0.01) earnings per share for the quarter. The company had revenue of C$0.04 million during the quarter.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name.
See Also
- Five stocks we like better than Kane Biotech
- How to Calculate Retirement Income: MarketBeat’s Calculator
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- What Are Dividend Contenders? Investing in Dividend Contenders
- Merger or Not, Albertson’s Companies is a Good Buy
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
